Neutralizing antibodies could potentially be used as antivirals against the coronavirus
disease 2019 (COVID-19) pandemic. Here, we report isolation of four human-origin …

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a
COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants,
especially the Omicron variant, have impaired the efficacy of existing vaccines and most …

Neutralizing antibodies for the treatment of COVID-19 | Nature Biomedical Engineering Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …

Dear Editor, The spread of the SARS-CoV-2 variants, especially the global variants of
concern (VOCs), could seriously dampen our efforts to tackle the COVID-19 pandemic. The …

As the coronavirus disease 2019 (COVID-19) pandemic continues, there is a strong need for
highly potent monoclonal antibodies (mAbs) that are resistant against severe acute …

The SARS-CoV-2 receptor binding domain (RBD) is both the principal target of neutralizing
antibodies and one of the most rapidly evolving domains, which can result in the emergence …

Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report
a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting …

Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …